Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CVT Ranexa complete response

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

CV Therapeutics submits its "complete response" to an October 2003 "approvable" letter for its angina treatment Ranexa (ranolazine) July 27. The amendment seeks a narrowed indication based on the FDA-requested ERICA (Evaluation of Ranolazine in Chronic Angina) study of patients refractory to Pfizer's Norvasc (amlodipine), which compared the partial fatty acid oxidation inhibitor plus the maximum labeled dose (10 mg) of Norvasc to Norvasc alone. CVT has said that the 0.4 attack/week reduction seen in ERICA was sufficient for an indication for a restricted population, despite being less than half the projected 1.0-1.2 reduction (1Pharmaceutical Approvals Monthly May 2005, p. 10). Assuming a six-month review of the amendment, Ranexa could launch in the first half of 2006...

You may also be interested in...



Ranexa Angina Reduction Enough For Restricted Indication, CVT Says

A mean weekly reduction of 0.4 angina attacks seen in the ERICA study with CV Therapeutics' Ranexa (ranolazine) is adequate for approval, the company said, despite being less than half the expected decrease

‘We Need Your COVID-19 Testing capacity’ UK Health Secretary Tells Life Science Firms

The UK has an “excellent but small diagnostics industry,” so it needs further testing support from related life science industries to tackle the COVID-19 crisis. One of the outcomes of this could be the creation of new big diagnostics industry players.

Drug/Device Combinations: New Position Paper Explains Notified Body Responsibilities

Medicinal products authorities will consider a medtech notified body opinion on the device element of a drug/device combination product. A new position paper explains how roles and responsibilities are shared between medtech and medicinal product experts.

Topics

UsernamePublicRestriction

Register

PS002990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel